Other Species / Isoforms
  JAK1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y3
_____MQyLNIKEDC
0 1
JAK1 (human) _____MQyLNIKEDC Y3
JAK1 (mouse) _____MQYLNIKEDC Y3
JAK1 (rat) PPRSSRQLLTRSGVR L30
Y107
KMSLRLHYRMRFYFT
0 2
JAK1 (human) KMSLRLHYRMRFYFT Y107
JAK1 (mouse) KTSLRLHYRMRFYFT Y107
JAK1 (rat) KMSLRLHyRMRFYFT Y152
S216
PELPKDIsyKRyIPE
0 1
JAK1 (human) PELPKDIsyKRyIPE S216
JAK1 (mouse) PELPKDISYKRYIPE S216
JAK1 (rat) PELPKDISYKRYIPE S261
Y217
ELPKDIsyKRyIPET
0 2
JAK1 (human) ELPKDIsyKRyIPET Y217
JAK1 (mouse) ELPKDISYKRYIPET Y217
JAK1 (rat) ELPKDISYKRYIPET Y262
Y220
KDIsyKRyIPETLNK
Upstream
0 2
Treatment
  • IFN-alpha
JAK1 (human) KDIsyKRyIPETLNK Y220
JAK1 (mouse) KDISYKRYIPETLNK Y220
JAK1 (rat) KDISYKRYIPETLNK Y265
S228
IPETLNKsIRQRNLL
Upstream
0 2
Treatment
  • IL-2
JAK1 (human) IPETLNKsIRQRNLL S228
JAK1 (mouse) IPETLNKSIRQRNLL S228
JAK1 (rat) IPETLNKSIRQRNLL S273
T236
IRQRNLLTRMRINNV
0 1
JAK1 (human) IRQRNLLTRMRINNV T236
JAK1 (mouse) IRQRNLLtRMRINNV T236
JAK1 (rat) IRQRNLLTRMRINNV T281
S333
RHKPNVVsVEKEKNK
Upstream
0 1
Treatment
  • IL-2
JAK1 (human) RHKPNVVsVEKEKNK S333
JAK1 (mouse) RQKPNVVPVEKEKNK P332
JAK1 (rat) RQKPNVLPVEKEKNK P377
Y507
IEVQKGRySLHGSDR
0 1
JAK1 (human) IEVQKGRySLHGSDR Y507
JAK1 (mouse) IEVQKGRYSLHGSMD Y506
JAK1 (rat) IEVQKGRYSLHGSVD Y551
S515
SLHGSDRsFPsLGDL
Upstream
Downstream
1 0
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • AMPKA1 (human)
JAK1 (human) SLHGSDRsFPsLGDL S515
JAK1 (mouse) SLHGSMDHFPSLRDL H514
JAK1 (rat) SLHGSVDHFPSLRDL H559
S518
GSDRsFPsLGDLMsH
Upstream
Downstream
1 0
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • AMPKA1 (human)
JAK1 (human) GSDRsFPsLGDLMsH S518
JAK1 (mouse) GSMDHFPSLRDLMNH S517
JAK1 (rat) GSVDHFPSLRDLMNH S562
S524
PsLGDLMsHLKKQIL
0 1
JAK1 (human) PsLGDLMsHLKKQIL S524
JAK1 (mouse) PSLRDLMNHLKKQIL N523
JAK1 (rat) PSLRDLMNHLKKQIL N568
Y568
AQEWQPVyPMSQLsF
0 1
JAK1 (human) AQEWQPVyPMSQLsF Y568
JAK1 (mouse) AQEWQPVYSMSQLSF Y567
JAK1 (rat) AQEWQPVYSMSQLSF Y612
S574
VyPMSQLsFDRILKK
Upstream
0 2
Treatment
  • IL-4
JAK1 (human) VyPMSQLsFDRILKK S574
JAK1 (mouse) VYSMSQLSFDRILKK S573
JAK1 (rat) VYSMSQLSFDRILKK S618
Y605
YSGTLMDyKDDEGTS
0 1
JAK1 (human) YSGTLMDyKDDEGTS Y605
JAK1 (mouse) YSGTLLDYKDEEGIA Y604
JAK1 (rat) YSGTLLDYKDDEGIA Y649
T687
HRKSDVLttPWKFKV
0 1
JAK1 (human) HRKSDVLttPWKFKV T687
JAK1 (mouse) HRKSDALTTPWKFKV T686
JAK1 (rat) HRKSDALTTPWKFKV T731
T688
RKSDVLttPWKFKVA
0 1
JAK1 (human) RKSDVLttPWKFKVA T688
JAK1 (mouse) RKSDALTTPWKFKVA T687
JAK1 (rat) RKSDALTTPWKFKVA T732
S738
CGPFIKLsDPGIPIT
0 1
JAK1 (human) CGPFIKLsDPGIPIT S738
JAK1 (mouse) IGPFIKLSDPGIPVS S737
JAK1 (rat) IGPFIKLSDPGIPVS S782
S857
EQNPDIVsEKKPATE
0 1
JAK1 (human) EQNPDIVsEKKPATE S857
JAK1 (mouse) EQNPDIVSEKQPTTE S856
JAK1 (rat) EQNPDIVSEKQPITE S901
Y940
YHENIVKYKGICTED
1 0
JAK1 (human) YHENIVKYKGICTED Y940
JAK1 (mouse) YHENIVKyKGICMED Y939
JAK1 (rat) YHENIVKYKGICMED Y984
Y967
PSGSLKEyLPKNKNK
0 1
JAK1 (human) PSGSLKEyLPKNKNK Y967
JAK1 (mouse) PSGSLKEYLPKNKNK Y966
JAK1 (rat) PSGSLKEYLPKNKNK Y1011
Y993
QICKGMDyLGSRQYV
0 1
JAK1 (human) QICKGMDyLGSRQYV Y993
JAK1 (mouse) QICKGMDYLGSRQYV Y992
JAK1 (rat) QICKGMDYLGSRQYV Y1037
T1030
GLTKAIEtDKEyytV
0 2
JAK1 (human) GLTKAIEtDKEyytV T1030
JAK1 (mouse) GLTKAIEtDKEyyTV T1029
JAK1 (rat) GLTKAIETDKEYYTV T1074
Y1034
AIEtDKEyytVKDDR
Upstream
Downstream
27 178
JAK1 (human)
Y1034
JAK1 (mouse)
Y1033
JAK1 (rat)
Y1078
Effects on Biological Processes:
  • carcinogenesis, induced
Kinase, in vitro:
  • JAK3 (human)
Putative upstream phosphatases:
  • PTPN2 (human)
Regulatory protein:
  • SOCS3 (mouse)
  • Tyk2 (human)
Treatment
  • 2-deoxyglucose
  • AG490
  • antibody
  • As3+
  • cryptotanshinone
  • FGF1
  • gambogic_acid
  • gefitinib
  • H2O2
  • IFN-alpha
  • IFN-beta
  • IFN-gamma
  • IL-10
  • IL-2
  • IL-6
  • JAK_inhibitor_I
  • leptin
  • methimazole
  • PD173074
  • PP2
  • U0126
  • vanadate
  • virus infection
JAK1 (human) AIEtDKEyytVKDDR Y1034
JAK1 (mouse) AIEtDKEyyTVKDDR Y1033
JAK1 (rat) AIETDKEYYTVKDDR Y1078
Y1035
IEtDKEyytVKDDRD
Upstream
Downstream
26 53
JAK1 (human)
Y1035
JAK1 (mouse)
Y1034
JAK1 (rat)
Y1079
Effects on Biological Processes:
  • carcinogenesis, induced
Kinase, in vitro:
  • JAK3 (human)
Putative upstream phosphatases:
  • PTPN2 (human)
Regulatory protein:
  • SOCS3 (mouse)
  • Tyk2 (human)
Treatment
  • AG490
  • antibody
  • As3+
  • cryptotanshinone
  • gambogic_acid
  • H2O2
  • IFN-alpha
  • IFN-beta
  • IFN-gamma
  • IL-10
  • IL-2
  • IL-6
  • JAK_inhibitor_I
  • leptin
  • methimazole
  • PP2
  • vanadate
  • virus infection
JAK1 (human) IEtDKEyytVKDDRD Y1035
JAK1 (mouse) IEtDKEyyTVKDDRD Y1034
JAK1 (rat) IETDKEYYTVKDDRD Y1079
T1036
EtDKEyytVKDDRDs
0 5
JAK1 (human) EtDKEyytVKDDRDs T1036
JAK1 (mouse) EtDKEyyTVKDDRDS T1035
JAK1 (rat) ETDKEYYTVKDDRDS T1080
S1043
tVKDDRDsPVFWYAP
0 2
JAK1 (human) tVKDDRDsPVFWYAP S1043
JAK1 (mouse) TVKDDRDSPVFWYAP S1042
JAK1 (rat) TVKDDRDSPVFWYAP S1087
T1107
TVTRLVNtLKEGKRL
0 1
JAK1 (human) TVTRLVNtLKEGKRL T1107
JAK1 (mouse) TVTRLVKTLKEGKRL T1106
JAK1 (rat) TVTRLVNTLKEGKRL T1151
Y1125
PNCPDEVyQLMRKCW
0 38
JAK1 (human) PNCPDEVyQLMRKCW Y1125
JAK1 (mouse) PNCPDEVYQLMRKCW Y1124
JAK1 (rat) PNCPDEVYQLMRKCW Y1169